{"id":"neoadjuvant-ipilimumab-nivolumab","safety":{"commonSideEffects":[{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Rash"},{"rate":null,"effect":"Immune-related pneumonitis"},{"rate":null,"effect":"Immune-related hepatitis"},{"rate":null,"effect":"Immune-related colitis"}]},"_chembl":{"chemblId":"CHEMBL1789844","moleculeType":"Antibody"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Ipilimumab is a CTLA-4 inhibitor that removes inhibitory signals on T cells, while nivolumab is a PD-1 inhibitor that prevents tumor cells from suppressing T cell activity. Together, they synergistically activate the immune system to attack cancer cells in the neoadjuvant setting (before surgery), aiming to improve pathologic complete response rates and surgical outcomes.","oneSentence":"This combination blocks two immune checkpoints (PD-1 and CTLA-4) to enhance anti-tumor immune responses before surgical resection.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:50:20.504Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Neoadjuvant treatment of resectable melanoma"},{"name":"Neoadjuvant treatment of resectable non-small cell lung cancer"}]},"trialDetails":[{"nctId":"NCT04751370","phase":"PHASE2","title":"Testing Nivolumab and Ipilimumab With Short-Course Radiation in Locally Advanced Rectal Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2022-02-08","conditions":"Locally Advanced Rectal Adenocarcinoma, Stage II Rectal Cancer AJCC v8, Stage III Rectal Cancer AJCC v8","enrollment":31},{"nctId":"NCT02339571","phase":"PHASE2, PHASE3","title":"A Phase II/III Trial of Nivolumab, Ipilimumab, and GM-CSF in Patients With Advanced Melanoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2015-11-23","conditions":"Stage III Cutaneous Melanoma AJCC v7, Stage IV Cutaneous Melanoma AJCC v6 and v7","enrollment":600},{"nctId":"NCT03026140","phase":"PHASE2","title":"Neoadjuvant Immune Checkpoint Inhibition and Novel IO Combinations in Early-stage Colon Cancer","status":"RECRUITING","sponsor":"The Netherlands Cancer Institute","startDate":"2017-03-29","conditions":"Colon Carcinoma","enrollment":353},{"nctId":"NCT03307616","phase":"PHASE2","title":"Nivolumab With and Without Ipilimumab and Radiation Therapy in Treating Patients With Recurrent or Resectable Undifferentiated Pleomorphic Sarcoma or Dedifferentiated Liposarcoma Before Surgery","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2017-10-04","conditions":"Dedifferentiated Liposarcoma, Recurrent Dedifferentiated Liposarcoma, Recurrent Undifferentiated Pleomorphic Sarcoma","enrollment":32},{"nctId":"NCT05647265","phase":"PHASE2","title":"Testing the Addition of Immunotherapy Before Surgery for Patients With Sarcomatoid Mesothelioma","status":"RECRUITING","sponsor":"Alliance for Clinical Trials in Oncology","startDate":"2024-11-27","conditions":"Pleural Biphasic Mesothelioma, Pleural Sarcomatoid Mesothelioma","enrollment":26},{"nctId":"NCT06587451","phase":"PHASE3","title":"Integrated Pharmacokinetics (PK)/Efficacy, Safety, and Immunogenicity Study to Demonstrate Similarity of JPB898, a Proposed Biosimilar to Nivolumab, to Opdivo® in Combination With Yervoy®","status":"TERMINATED","sponsor":"Sandoz","startDate":"2024-12-19","conditions":"Melanoma","enrollment":52},{"nctId":"NCT06999980","phase":"PHASE2","title":"Neo IRENIE (NEOadjuvant Ipilimumab, RElatlimab, NIvolumab Evaluation)","status":"RECRUITING","sponsor":"Melanoma Institute Australia","startDate":"2026-02-09","conditions":"Cutaneous Melanoma, Mucosal Melanoma","enrollment":494},{"nctId":"NCT03520491","phase":"PHASE2","title":"A Study to Test the Safety of Immunotherapy With Nivolumab Alone or With Ipilimumab Before Surgery for Bladder Cancer Patients Who Are Not Suitable for Chemotherapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2018-04-25","conditions":"Bladder Cancer","enrollment":52},{"nctId":"NCT04606316","phase":"PHASE1","title":"Surgical Nivolumab And Ipilimumab For Recurrent GBM","status":"ACTIVE_NOT_RECRUITING","sponsor":"Patrick Wen, MD","startDate":"2021-02-01","conditions":"Glioblastoma, GBM, Glioblastoma Multiforme","enrollment":63},{"nctId":"NCT07403877","phase":"PHASE2","title":"Neoadjuvant Immunotherapy ± Radiotherapy in MSI-H/dMMR Locally Advanced Colorectal Cancer","status":"NOT_YET_RECRUITING","sponsor":"Fudan University","startDate":"2026-02-01","conditions":"Colorectal Cancer (MSI-H)","enrollment":114},{"nctId":"NCT04080804","phase":"PHASE2","title":"Study of Safety and Tolerability of Nivolumab Treatment Alone or in Combination With Relatlimab or Ipilimumab in Head and Neck Cancer","status":"RECRUITING","sponsor":"Dan Zandberg","startDate":"2019-12-20","conditions":"Head and Neck Squamous Cell Carcinoma (HNSCC)","enrollment":80},{"nctId":"NCT05358938","phase":"EARLY_PHASE1","title":"Exercise to Boost Response to Checkpoint Blockade Immunotherapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2022-06-21","conditions":"Cutaneous Melanoma, Cutaneous Squamous Cell Carcinoma, Merkel Cell Carcinoma","enrollment":22},{"nctId":"NCT06365619","phase":"PHASE2","title":"Neoadjuvant Ipilimumab/Nivolumab for Patients With Recurrent, High Risk, Resectable Melanoma","status":"RECRUITING","sponsor":"University of Utah","startDate":"2026-02","conditions":"Melanoma","enrollment":25},{"nctId":"NCT06295159","phase":"PHASE2","title":"Neoadjuvant and Adjuvant Anti-PD1 or Combinations for Locoregionally Advanced Melanoma","status":"RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2024-05-17","conditions":"Melanoma Stage III, Melanoma Stage IV, Advanced Melanoma","enrollment":90},{"nctId":"NCT02998528","phase":"PHASE3","title":"A Neoadjuvant Study of Nivolumab Plus Ipilimumab or Nivolumab Plus Chemotherapy Versus Chemotherapy Alone in Early Stage Non-Small Cell Lung Cancer (NSCLC)","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2017-03-04","conditions":"Non Small Cell Lung Cancer","enrollment":505},{"nctId":"NCT07315035","phase":"PHASE2","title":"QL1706-SOX vs SOX Alone as Neoadjuvant Therapy for Resectable Diffuse-Type Gastric Cancer","status":"NOT_YET_RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2026-01-01","conditions":"Gastric Cancer Stage III","enrollment":74},{"nctId":"NCT04933903","phase":"PHASE2","title":"BrUOG 397: NEO Rad (LOW): Neoadjuvant Low Dose Stereotactic Body Radiotherapy, Ipilimumab and Nivolumab","status":"RECRUITING","sponsor":"Brown University","startDate":"2021-10-05","conditions":"Non Small Cell Lung Cancer","enrollment":25},{"nctId":"NCT03245892","phase":"PHASE1","title":"A Study of Carboplatin and Paclitaxel Chemotherapy With Nivolumab With or Without Ipilimumab in Patients With Ovarian Cancer","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2017-08-04","conditions":"High Grade Serous Ovarian, Fallopian Tube, Primary Peritoneal Cancer","enrollment":27},{"nctId":"NCT06794775","phase":"PHASE3","title":"SWE-NEO: Swedish NeoAdjuvant Trial Comparing Monotherapy to Combined Immunotherapy in Resectable Stage III Melanoma","status":"RECRUITING","sponsor":"Hildur Helgadottir","startDate":"2025-07-10","conditions":"Malignant Melanoma Stage III","enrollment":128},{"nctId":"NCT07233668","phase":"NA","title":"Immediate Versus Deferred Cytoreductive Nephrectomy With Ipilimumab/Nivolumab in mRCC","status":"NOT_YET_RECRUITING","sponsor":"Seoul National University Hospital","startDate":"2025-12-01","conditions":"Metastatic Renal Cell Carcinoma ( mRCC)","enrollment":172},{"nctId":"NCT02259621","phase":"PHASE2","title":"Neoadjuvant Nivolumab, or Nivolumab in Combination With Ipilimumab, in Resectable NSCLC","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2014-09","conditions":"Non-Small Cell Lung Cancer","enrollment":39},{"nctId":"NCT07091695","phase":"","title":"Real-world Outcomes Among Patients With Melanoma Treated With Neoadjuvant Nivolumab+Relatlimab or Nivolumab+Ipilimumab","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2025-05-11","conditions":"Melanoma","enrollment":100},{"nctId":"NCT04013854","phase":"PHASE2","title":"Adjuvant Treatment Determined By Pathological Response To Neoadjvuant Nivolumab","status":"ACTIVE_NOT_RECRUITING","sponsor":"Abramson Cancer Center at Penn Medicine","startDate":"2020-01-01","conditions":"Melanoma Stage III, Melanoma","enrollment":67},{"nctId":"NCT05289193","phase":"PHASE2","title":"CD8+ T Cell Imaging During Pre-surgery Immunotherapy in People With Melanoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2022-03-11","conditions":"Melanoma, Melanoma Stage III","enrollment":28},{"nctId":"NCT04465643","phase":"PHASE1","title":"Neoadjuvant Nivolumab Plus Ipilimumab for Newly Diagnosed Malignant Peripheral Nerve Sheath Tumor","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2021-06-08","conditions":"Nerve Sheath Tumors","enrollment":13},{"nctId":"NCT05148546","phase":"PHASE2","title":"Neoadjuvant Study With Combination Immuno-oncology for Primary Clear Cell Renal Cell Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"The Netherlands Cancer Institute","startDate":"2022-04-28","conditions":"Renal Cell Carcinoma","enrollment":69},{"nctId":"NCT03075423","phase":"PHASE2","title":"Randomized Phase-II Study of Nivolumab Plus Ipilimumab vs. Standard of Care in Untreated and Advanced Non-clear Cell RCC","status":"COMPLETED","sponsor":"Goethe University","startDate":"2017-11-01","conditions":"Metastatic Renal Cell Carcinoma","enrollment":316},{"nctId":"NCT07121374","phase":"PHASE1, PHASE2","title":"NEoadjuvant Chemotherapy and Immunotherapy for a Selected Group of Inoperable Pleural Mesothelioma Patients (NECIM): a Feasibility Study","status":"RECRUITING","sponsor":"University Hospital, Antwerp","startDate":"2025-07-22","conditions":"Pleural Epithelioid Mesothelioma, Mesothelioma; Pleura, Neoadjuvant Chemoimmunotherapy","enrollment":37},{"nctId":"NCT03463408","phase":"EARLY_PHASE1","title":"Immunotherapy + Radiation in Resectable Soft Tissue Sarcoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Rochester","startDate":"2018-07-17","conditions":"Sarcoma","enrollment":14},{"nctId":"NCT04620200","phase":"PHASE2","title":"Neo-adjuvant Nivolumab or Nivolumab With Ipilimumab in Advanced Cutaneous Squamous Cell Carcinoma Prior to Surgery","status":"COMPLETED","sponsor":"The Netherlands Cancer Institute","startDate":"2020-08-11","conditions":"Cutaneous Squamous Cell Carcinoma","enrollment":50},{"nctId":"NCT06754904","phase":"NA","title":"Omitting Therapeutic Lymph Node Dissection in Patients With Melanoma (Stage 3) and Major Pathological Response in the Index Lymph Node","status":"RECRUITING","sponsor":"D.J. (Dirk) Grünhagen","startDate":"2025-04-23","conditions":"Melanoma, Skin","enrollment":213},{"nctId":"NCT03350126","phase":"PHASE2","title":"iRECIST Evaluation's Relevance for DCR in MMR/MSI Metastatic Colorectal Cancer Patients on Nivolumab and Ipilimumab","status":"ACTIVE_NOT_RECRUITING","sponsor":"GERCOR - Multidisciplinary Oncology Cooperative Group","startDate":"2017-12-04","conditions":"Metastatic Cancer Colorectal","enrollment":57},{"nctId":"NCT05310643","phase":"PHASE2","title":"Nivolumab and Ipilimumab in Anti-PD1-Resistant dMMR/MSI mCRC","status":"RECRUITING","sponsor":"GERCOR - Multidisciplinary Oncology Cooperative Group","startDate":"2022-05-05","conditions":"Metastatic Colorectal Cancer","enrollment":30},{"nctId":"NCT03918252","phase":"PHASE2","title":"Neoadjuvant Immune Checkpoint Blockade in Resectable Malignant Pleural Mesothelioma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2019-10-02","conditions":"Mesothelioma","enrollment":30},{"nctId":"NCT03977571","phase":"NA","title":"Deferred Cytoreductive Nephrectomy in Synchronous Metastatic Renal Cell Carcinoma: The NORDIC-SUN-Trial","status":"RECRUITING","sponsor":"Niels Fristrup","startDate":"2020-07-06","conditions":"Kidney Cancer, Renal Cell Carcinoma Metastatic, Synchronous Neoplasm","enrollment":400},{"nctId":"NCT06823479","phase":"PHASE2","title":"Towards Cure Via Only Ultra-short ICB in CSCC","status":"RECRUITING","sponsor":"The Netherlands Cancer Institute","startDate":"2025-05-14","conditions":"Cutaneous Squamous Cell Carcinoma (CSCC), Cutaneous Squamous Cell Cancer, Cutaneous Squamous Cell Carcinoma of the Head and Neck","enrollment":41},{"nctId":"NCT03618641","phase":"PHASE2","title":"CMP-001 in Combo With Nivolumab in Stage IIIB/C/D Melanoma Patients With Clinically Apparent Lymph Node Disease","status":"COMPLETED","sponsor":"Diwakar Davar","startDate":"2018-08-08","conditions":"Melanoma, Lymph Node Cancer","enrollment":34},{"nctId":"NCT06926790","phase":"PHASE2","title":"Neoadjuvant Nivolumab Plus Ipilimumab in Resectable NSCLC (GALAXY 3)","status":"RECRUITING","sponsor":"The First Affiliated Hospital of Guangzhou Medical University","startDate":"2025-02-17","conditions":"Lung Cancer - Non Small Cell","enrollment":69},{"nctId":"NCT04133948","phase":"PHASE1, PHASE2","title":"Multicenter Phase 1b Trial Testing the Neoadjuvant Combination of Domatinostat, Nivolumab and Ipilimumab in IFN-gamma Signature-low and IFN-gamma Signature-high RECIST 1.1-measurable Stage III Cutaneous or Unknown Primary Melanoma","status":"COMPLETED","sponsor":"The Netherlands Cancer Institute","startDate":"2020-01-07","conditions":"Malignant Melanoma Stage III","enrollment":44},{"nctId":"NCT05302921","phase":"PHASE2","title":"Neoadjuvant Dual Checkpoint Inhibition and Cryoablation in Relapsed/Refractory Pediatric Solid Tumors","status":"COMPLETED","sponsor":"Children's National Research Institute","startDate":"2022-02-18","conditions":"Osteosarcoma, Ewing Sarcoma, Rhabdomyosarcoma","enrollment":5},{"nctId":"NCT06240143","phase":"PHASE1, PHASE2","title":"Intradermal Ipilimumab and Nivolumab in High Risk Stage II Melanoma","status":"RECRUITING","sponsor":"The Netherlands Cancer Institute","startDate":"2024-03-08","conditions":"Melanoma","enrollment":96},{"nctId":"NCT04401995","phase":"PHASE2","title":"Study of TLR9 Agonist Vidutolimod (CMP-001) in Combination with Nivolumab Vs. Nivolumab","status":"COMPLETED","sponsor":"Diwakar Davar","startDate":"2020-09-02","conditions":"Melanoma","enrollment":9},{"nctId":"NCT06566391","phase":"PHASE2","title":"Ipilimumab and Nivolumab Followed by Adjuvant Nivolumab in Locally Advanced or Limited Metastatic Melanoma","status":"UNKNOWN","sponsor":"European Institute of Oncology","startDate":"2019-03-05","conditions":"Melanoma","enrollment":35},{"nctId":"NCT03510871","phase":"PHASE2","title":"Nivolumab Plus Ipilimumab as Neoadjuvant Therapy for Hepatocellular Carcinoma (HCC)","status":"COMPLETED","sponsor":"National Health Research Institutes, Taiwan","startDate":"2019-02-12","conditions":"Hepatocellular Carcinoma (HCC)","enrollment":43},{"nctId":"NCT04124601","phase":"PHASE2","title":"Neoadjuvant Chemoradiotherapy With Sequential Ipilimumab and Nivolumab in Rectal Cancer","status":"COMPLETED","sponsor":"Johannes Laengle, MD, PhD","startDate":"2020-06-01","conditions":"Rectal Cancer","enrollment":80},{"nctId":"NCT02519322","phase":"PHASE2","title":"Neoadjuvant and Adjuvant Checkpoint Blockade","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2016-02-02","conditions":"Cutaneous Melanoma, Mucosal Melanoma, Ocular Melanoma","enrollment":53},{"nctId":"NCT04949113","phase":"PHASE3","title":"Neoadjuvant Ipilimumab Plus Nivolumab Versus Standard Adjuvant Nivolumab in Macroscopic Stage III Melanoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"The Netherlands Cancer Institute","startDate":"2021-07-08","conditions":"Malignant Melanoma Stage III","enrollment":423},{"nctId":"NCT03818685","phase":"PHASE2","title":"Evaluate the Clinical Benefit of a Post-operative Treatment Associating Radiotherapy + Nivolumab + Ipilimumab Versus Radiotherapy + Capecitabine for Triple Negative Breast Cancer Patients With Residual Disease","status":"UNKNOWN","sponsor":"Centre Leon Berard","startDate":"2019-07-02","conditions":"Breast Cancer, Triple Negative Breast Neoplasms","enrollment":95},{"nctId":"NCT05492123","phase":"PHASE2","title":"Nivolumab-ipilimumab and Chemoradiation for Cervical Cancer","status":"RECRUITING","sponsor":"Hospital Israelita Albert Einstein","startDate":"2022-08-30","conditions":"Uterine Cervical Neoplasms","enrollment":112},{"nctId":"NCT02488759","phase":"PHASE1, PHASE2","title":"An Investigational Immuno-therapy Study to Investigate the Safety and Effectiveness of Nivolumab, and Nivolumab Combination Therapy in Virus-associated Tumors","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2015-10-13","conditions":"Various Advanced Cancer","enrollment":578},{"nctId":"NCT03003637","phase":"PHASE1, PHASE2","title":"ImmunoModulation by the Combination of Ipilimumab and Nivolumab Neoadjuvant to Surgery In Advanced or Recurrent Head and Neck Carcinoma","status":"COMPLETED","sponsor":"The Netherlands Cancer Institute","startDate":"2017-02-28","conditions":"Immunotherapy, Head and Neck Neoplasms","enrollment":33},{"nctId":"NCT05753839","phase":"NA","title":"The Role of Cytoreductive Nephrectomy in Metastatic Renal Cell Carcinoma in Immuno-oncology Era: SEVURO-CN Trial","status":"RECRUITING","sponsor":"Yonsei University","startDate":"2023-07","conditions":"Kidney Cancer, Clear Cell Renal Cell Carcinoma Metastatic, Synchronous Neoplasm","enrollment":40},{"nctId":"NCT03700905","phase":"PHASE3","title":"Study of Nivolumab Alone or in Combination With Ipilimumab as Immunotherapy vs Standard Follow-up in Surgical Resectable HNSCC After Adjuvant Therapy","status":"UNKNOWN","sponsor":"Universitätsklinikum Hamburg-Eppendorf","startDate":"2018-08-21","conditions":"Head and Neck Cancer","enrollment":276},{"nctId":"NCT02449837","phase":"","title":"Investigation of Circulating Tumor Cells From Cancer Patients Undergoing Radiation Therapy","status":"COMPLETED","sponsor":"UNC Lineberger Comprehensive Cancer Center","startDate":"2014-05","conditions":"Circulating Tumor Cells","enrollment":162},{"nctId":"NCT04434560","phase":"PHASE2","title":"Neoadjuvant Immunotherapy in Brain Metastases","status":"TERMINATED","sponsor":"Sarah Sammons, MD","startDate":"2020-11-04","conditions":"Brain Metastases, Adult","enrollment":1},{"nctId":"NCT03342417","phase":"PHASE2","title":"Combination of Nivolumab and Ipilimumab in Breast, Ovarian and Gastric Cancer Patients","status":"TERMINATED","sponsor":"ExcellaBio LLC","startDate":"2018-02-14","conditions":"Breast Cancer Female, Ovarian Cancer, Gastric Cancer","enrollment":5},{"nctId":"NCT04495010","phase":"PHASE2","title":"Neoadjuvant Nivolumab+Ipilimumab Followed by Adjuvant Nivolumab or Neoadjuvant Nivolumab+Ipilimumab Followed by Adjuvant Observation Compared With Adjuvant Nivolumab in Treatment-Naive High-risk Melanoma Participants","status":"WITHDRAWN","sponsor":"Bristol-Myers Squibb","startDate":"2021-03-31","conditions":"Melanoma","enrollment":""},{"nctId":"NCT02968303","phase":"PHASE2","title":"Induction Therapy With Vemurafenib and Cobimetinib to Optimize Nivolumab and Ipilimumab Therapy","status":"UNKNOWN","sponsor":"Radboud University Medical Center","startDate":"2017-01-27","conditions":"Melanoma, Malignant, of Soft Parts","enrollment":200},{"nctId":"NCT04007588","phase":"PHASE2","title":"A Phase II Trial of Neoadjuvant Treatment With PD-1 Inhibition (Nivolumab) With or Without IDO Inhibition (BMS-986205) and With or Without CTLA-4 Inhibition (Ipilimumab) in Resectable Stage III or IV Melanoma","status":"WITHDRAWN","sponsor":"Dana-Farber Cancer Institute","startDate":"2019-09-06","conditions":"Melanoma Stage III, Melanoma Stage IV","enrollment":""},{"nctId":"NCT03220009","phase":"PHASE2","title":"Nivolumab or Expectant Observation Following Ipilimumab, Nivolumab, and Surgery in Treating Patients With High Risk Localized, Locoregionally Advanced, or Recurrent Mucosal Melanoma","status":"WITHDRAWN","sponsor":"National Cancer Institute (NCI)","startDate":"2017-11-03","conditions":"Cervical Carcinoma, Esophageal Carcinoma, Mucosal Melanoma","enrollment":""},{"nctId":"NCT02736123","phase":"PHASE1, PHASE2","title":"Neoadjuvant Combination Biotherapy With Ipilimumab and Nivolumab or Nivolumab Alone","status":"WITHDRAWN","sponsor":"University of Pittsburgh","startDate":"2016-10","conditions":"Melanoma","enrollment":""}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Yervoy + Opdivo"],"phase":"phase_3","status":"active","brandName":"Neoadjuvant ipilimumab + nivolumab","genericName":"Neoadjuvant ipilimumab + nivolumab","companyName":"The Netherlands Cancer Institute","companyId":"the-netherlands-cancer-institute","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This combination blocks two immune checkpoints (PD-1 and CTLA-4) to enhance anti-tumor immune responses before surgical resection. Used for Neoadjuvant treatment of resectable melanoma, Neoadjuvant treatment of resectable non-small cell lung cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}